![Florence Allouche Aknin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Florence Allouche Aknin
Président chez
PEPKON
Profil
Florence Allouche Aknin currently works at PEPKON, as Chairman, NLS Pharmaceutics Ltd., as Independent Director from 2024, Académie nationale de Pharmacie, as Member, and Universite Paris Cite, as Professor.
Dr. Allouche Aknin also formerly worked at SparingVision SAS, as President & Chief Executive Officer from 2016 to 2020 and Génomic Vision SA, as Chairman from 2022 to 2023.
Postes actifs de Florence Allouche Aknin
| Sociétés | Poste | Début |
|---|---|---|
Universite Paris Cite
 Universite Paris Cite Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Académie nationale de Pharmacie | Corporate Officer/Principal | - |
PEPKON
 PEPKON BiotechnologyHealth Technology Operates as a biotechnology company that develops peptides for the treatment of incurable or poor prognosis cancers | Président | - |
Anciens postes connus de Florence Allouche Aknin
| Sociétés | Poste | Fin |
|---|---|---|
| GENOMIC VISION | Président | 01/10/2023 |
SparingVision SAS
 SparingVision SAS BiotechnologyHealth Technology Develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa | Directeur Général | 01/10/2020 |
| NLS PHARPAR | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
3
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Génomic Vision SA
 Génomic Vision SA Medical SpecialtiesHealth Technology Develops diagnostic tools using deoxyribonucleic acid analysis | Health Technology |
Académie nationale de Pharmacie | |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology Develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa | Health Technology |
NLS Pharmaceutics Ltd.
 NLS Pharmaceutics Ltd. Pharmaceuticals: MajorHealth Technology Develops drugs to treat mental and neurobehavioral disorders | Health Technology |
Universite Paris Cite
Universite Paris Cite Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PEPKON
PEPKON BiotechnologyHealth Technology Operates as a biotechnology company that develops peptides for the treatment of incurable or poor prognosis cancers | Health Technology |
Choisissez Zonebourse 
